Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257205 · ClinicalTrials.gov registry record · Phase 3
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 655
- Enrollment target
NCT00257205: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00257205 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 655 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00257205, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 655 participants
- Enrollment target
Study Summary
This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy, or biochemotherapy for the treatment of metastatic disease. The primary objective of this trial is to compare overall survival for patients with advanced melanoma who are randomized to receive CP-675,206 with that of patients who are randomized to receive either dacarbazine or temozolomide (investigator choice)
Interventions
- DRUG temozolomide
- DRUG dacarbazine
- DRUG CP-675,206
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 655 participants |
| Start Date | 2006-03 |
| Est. Completion | 2010-08 |
| Phase | Phase 3 |
What the finished NCT00257205 record still lists
NCT00257205 is an interventional study that assigns participants to a tested intervention. The registered 655 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (15% lower).
The record links to 0 conditions, and to 3 interventions - of which temozolomide is the first listed.
NCT00257205 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00257205 about?
NCT00257205 is a clinical study titled "CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy". This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy, or biochemotherapy for the treatment of metastatic disease. The primary objective of this trial is to compare overall survival for ...
What is the current status of trial NCT00257205?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 655 participants. The study started on 2006-03. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00257205?
The interventions under investigation include: temozolomide (DRUG), dacarbazine (DRUG), CP-675,206 (DRUG).
Who is sponsoring clinical trial NCT00257205?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00257205's enrollment target sits among peer trials
655 565th of 2000 higher than 1,434 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07145515 · 655 participants · NA
Enhancing Heart Allograft Function With the OCS Heart System Trial
- NCT05407129 · 656 participants · NA
Patients and Families Improving Safety in Hospitals by Actively Reporting Experiences
- NCT06127199 · 656 participants · NA
Contraceptive Efficacy Study of Ovaprene
- NCT03671044 · 657 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia